Quality and safety requirements for sustainable phage therapy products.
about
Bacteriophage Procurement for Therapeutic PurposesPhage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting DiseasesStrain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of InfectionφBO1E, a newly discovered lytic bacteriophage targeting carbapenemase-producing Klebsiella pneumoniae of the pandemic Clonal Group 258 clade II lineageThe Janus-Face of Bacteriophages across Human Body Habitats.Bacteriophages as Potential Treatment for Urinary Tract InfectionsGenetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus.Silk route to the acceptance and re-implementation of bacteriophage therapy.A bacteriophage journey at the European Medicines Agency.Bacteriophage therapy: a regulatory perspective.Genetically modified bacteriophages in applied microbiology.Paenibacillus larvae-Directed Bacteriophage HB10c2 and Its Application in American Foulbrood-Affected Honey Bee Larvae.Pseudomonas predators: understanding and exploiting phage-host interactions.Characterization of vB_SauM-fRuSau02, a Twort-Like Bacteriophage Isolated from a Therapeutic Phage Cocktail.Alternatives to antibiotics.Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release.Bacteriophage Production in Compliance with Regulatory Requirements.Guidelines to Compose an Ideal Bacteriophage Cocktail.Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.In Vitro Characteristics of Phages to Guide 'Real Life' Phage Therapy Suitability.Optimizing Propagation of Staphylococcus aureus Infecting Bacteriophage vB_SauM-phiIPLA-RODI on Staphylococcus xylosus Using Response Surface Methodology.The disparate effects of bacteriophages on antibiotic-resistant bacteriaBacteriophage Therapy: Clinical Trials and Regulatory HurdlesCharacterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101
P2860
Q26738479-ADC35D2B-5609-4218-AB2F-6779C33C12F7Q28069939-4C028A29-D9BE-4F86-9924-C6807D71E5EAQ28546694-EACCAFCA-FD50-40B4-B8EB-C352DFC1AC04Q30402653-4593DDDA-A0EE-4A1D-8456-B17BEBF0EFBDQ36060279-511D3830-4B28-4EAB-ABFD-C7EE47D08056Q36784640-CC5EF6B0-7CB8-408F-8E04-9F684C4BB07BQ37712935-A3D75EF0-36E1-4C3D-8C49-A99D7D339D38Q38381910-0380D976-CF7F-4F1B-A6FA-A05F67ED8574Q38560900-BF197A78-7F56-46B8-9F40-44D66FD2D536Q38805538-0A1FA38B-6E41-4B0D-A4FF-51A317EE3036Q38870317-5ADF470A-6BA0-4CB0-928E-07013FA0EFABQ38998688-CBD27917-7C5D-4F45-B904-894A479E05D3Q39397651-48A981CA-B98F-4BB2-8FFF-0A22B730B3F0Q40041460-85AEC947-674E-4744-A744-B2939372B8D7Q40733237-AE31FBD2-05DB-4C90-89A9-6378DEE6028DQ40867366-260BDACE-3AD5-4AC6-A1B4-81025D17B555Q41918244-FF8566EA-F5A4-456D-866C-F0A4C2F658DDQ50100571-14EBCFE4-5429-4D9E-B7CA-8DCF5072FBDEQ50100609-5E76864C-06F5-4327-97F6-86CF23B69C8AQ52604672-663C1A24-4FD8-4A29-86D2-9D6F80FF3C7DQ53699945-F2EC6690-E570-4FF9-812A-9A875329863AQ54247479-8C94A1DB-503E-4DB3-8E7B-5D57EE909295Q57283588-0D4EAE54-E296-4973-971D-DB3B4DEEFFE4Q58571995-7C533113-0321-41A2-896E-C84F140D7E47Q58757038-8F2B49D9-AD82-4D86-A951-6D24B94F14A5
P2860
Quality and safety requirements for sustainable phage therapy products.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Quality and safety requirements for sustainable phage therapy products.
@ast
Quality and safety requirements for sustainable phage therapy products.
@en
type
label
Quality and safety requirements for sustainable phage therapy products.
@ast
Quality and safety requirements for sustainable phage therapy products.
@en
prefLabel
Quality and safety requirements for sustainable phage therapy products.
@ast
Quality and safety requirements for sustainable phage therapy products.
@en
P2093
P2860
P50
P1476
Quality and safety requirements for sustainable phage therapy products.
@en
P2093
Alain Dublanchet
Andrzej Górski
Bob G Blasdel
Christine Rohde
Daniel De Vos
Elizabeth Kutter
Ewa Olchawa
Flavie Pouilot
Gilbert Verbeken
Gregory Resch
P2860
P304
P356
10.1007/S11095-014-1617-7
P50
P577
2015-01-14T00:00:00Z